[激肽释放酶在男性不育症中的临床评估]
[Clinical evaluation of kallikrein in male infertility].
作者信息
Takasaki N, Ogita T, Tonami H, Shimizu A, Ueno N, Okano H
出版信息
Hinyokika Kiyo. 1986 Sep;32(9):1313-8.
Kallikrein was orally administered to 44 patients with male infertility at a dose of 90 or 120 KU/day for three months. The sperm density, sperm motility and fertility index (F.I.) were improved in 51.1%, 37.2% and 38.9% of the treated patients, respectively. Statistical analysis showed that significant improvement was noted in sperm density and F.I. between before and after the treatment, but not in sperm motility, sperm volume nor sperm morphology. During the period of treatment, in these treated 44 patients, 4 patients (9.1%) succeeded in pregnancy.
向44名男性不育患者口服激肽释放酶，剂量为90或120KU/天，持续三个月。治疗患者中，精子密度、精子活力和生育指数（F.I.）分别有51.1%、37.2%和38.9%得到改善。统计分析表明，治疗前后精子密度和F.I.有显著改善，但精子活力、精液量和精子形态无显著改善。在治疗期间，这44名接受治疗的患者中有4名（9.1%）成功受孕。
Zotero 插件